These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9841392)

  • 21. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 22. Shrinking DNA diagnostics to fill the markets of the future.
    Hodgson J
    Nat Biotechnol; 1998 Aug; 16(8):725-7. PubMed ID: 9702768
    [No Abstract]   [Full Text] [Related]  

  • 23. Affymetrix in new patents row.
    Ledford H
    Nature; 2008 Jul; 454(7203):377. PubMed ID: 18650873
    [No Abstract]   [Full Text] [Related]  

  • 24. Why small matters.
    Nat Biotechnol; 2003 Oct; 21(10):1113. PubMed ID: 14520377
    [No Abstract]   [Full Text] [Related]  

  • 25. The size, operation, and technical capabilities of protein and nucleic acid core facilities.
    Williams KR; Niece RL; Atherton D; Fowler AV; Kutny R; Smith AJ
    FASEB J; 1988 Dec; 2(15):3124-30. PubMed ID: 3192042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 27. Patent watch: Diagnostic patents at risk after Federal Circuit decisions.
    Noonan K
    Nat Rev Drug Discov; 2016 Jun; 15(6):377. PubMed ID: 27199249
    [No Abstract]   [Full Text] [Related]  

  • 28. Auctioning the cure.
    Willyard C
    Nat Med; 2011 May; 17(5):528-30. PubMed ID: 21546960
    [No Abstract]   [Full Text] [Related]  

  • 29. Negotiating the RNAi patent thicket.
    Schmidt C
    Nat Biotechnol; 2007 Mar; 25(3):273-5. PubMed ID: 17344871
    [No Abstract]   [Full Text] [Related]  

  • 30. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 31. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 32. Patent office resurrects EST debate.
    Chahine K
    Nat Biotechnol; 1998 Aug; 16(8):711. PubMed ID: 9702759
    [No Abstract]   [Full Text] [Related]  

  • 33. Application of four dyes in gene expression analyses by microarrays.
    Staal YC; van Herwijnen MH; van Schooten FJ; van Delft JH
    BMC Genomics; 2005 Jul; 6():101. PubMed ID: 16042794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uncertainty over pharmaceutical and biotech product patents in Pakistan.
    Sadaf S; Akhtar MW; Iqbal Z
    Nat Biotechnol; 2012 Dec; 30(12):1198-200. PubMed ID: 23222786
    [No Abstract]   [Full Text] [Related]  

  • 35. Navigating biotechnology's new fiscal opportunities.
    Purcell DJ
    Nat Biotechnol; 1998 May; 16 Suppl():51-3. PubMed ID: 9591271
    [No Abstract]   [Full Text] [Related]  

  • 36. Patenting race.
    Kahn J
    Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 38. [Ultrafast analysis of DNA by microchip and nanochip technology].
    Baba Y
    Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):76-85. PubMed ID: 10643337
    [No Abstract]   [Full Text] [Related]  

  • 39. Hatch-waxman changes debated.
    Chahine K
    Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
    [No Abstract]   [Full Text] [Related]  

  • 40. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.